Notable
MT101-5 · Early Parkinson's Disease
Primary completion pushed from Jul 2025 to Jan 2028
Also in this update: Study completion pushed from Sep 2025 to Mar 2028
Mthera Pharma Co., Ltd.Phase 2 NCT06175767 Registry history of NCT06175767 on ClinicalTrials.gov (opens the registry)